HK1211475A1 - Combination therapy - Google Patents

Combination therapy Download PDF

Info

Publication number
HK1211475A1
HK1211475A1 HK15112282.5A HK15112282A HK1211475A1 HK 1211475 A1 HK1211475 A1 HK 1211475A1 HK 15112282 A HK15112282 A HK 15112282A HK 1211475 A1 HK1211475 A1 HK 1211475A1
Authority
HK
Hong Kong
Prior art keywords
combination therapy
agent
pharmaceutically acceptable
acceptable salt
inhibitor
Prior art date
Application number
HK15112282.5A
Other languages
English (en)
Chinese (zh)
Inventor
Shivang Doshi
Sunkyu Kim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1211475A1 publication Critical patent/HK1211475A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15112282.5A 2012-11-28 2013-11-25 Combination therapy HK1211475A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730661P 2012-11-28 2012-11-28
US61/730,661 2012-11-28
PCT/US2013/071659 WO2014085318A1 (en) 2012-11-28 2013-11-25 Combination therapy

Publications (1)

Publication Number Publication Date
HK1211475A1 true HK1211475A1 (en) 2016-05-27

Family

ID=49753505

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112282.5A HK1211475A1 (en) 2012-11-28 2013-11-25 Combination therapy

Country Status (12)

Country Link
US (1) US9408847B2 (https=)
EP (1) EP2925365A1 (https=)
JP (2) JP2016501221A (https=)
KR (1) KR20150089053A (https=)
CN (1) CN104812414A (https=)
AU (4) AU2013352406A1 (https=)
BR (1) BR112015012197A8 (https=)
CA (1) CA2891938A1 (https=)
HK (1) HK1211475A1 (https=)
MX (1) MX2015006809A (https=)
RU (1) RU2015125307A (https=)
WO (1) WO2014085318A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2726074B1 (en) * 2011-07-01 2018-04-04 Novartis AG Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
ME03557B (me) 2013-03-15 2020-07-20 G1 Therapeutics Inc Privremena zaštiтa normalnih ćelija током hemoterapije
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
ES3055185T3 (en) 2014-03-28 2026-02-10 Univ Duke Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
CN106336412A (zh) * 2015-07-10 2017-01-18 南开大学 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
EP3156406A1 (en) * 2015-10-14 2017-04-19 ratiopharm GmbH Crystalline forms of ribociclib free base
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
MX389702B (es) * 2016-06-22 2025-03-20 Ellipses Pharma Ltd Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
WO2018081211A1 (en) * 2016-10-26 2018-05-03 Li George Y Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
MX2019010981A (es) * 2017-03-16 2020-09-07 Eisai R&D Man Co Ltd Terapias de combinacion para el tratamiento de cancer de mama.
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
MY204117A (en) 2017-06-22 2024-08-08 Novartis Ag Antibody molecules to cd73 and uses thereof
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2020103922A1 (en) * 2018-11-23 2020-05-28 Ascentage Pharma (Suzhou) Co., Ltd. Novel pharmaceutical composition and use thereof
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2558092B1 (en) * 2010-04-13 2018-06-27 Novartis AG Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer

Also Published As

Publication number Publication date
AU2013352406A1 (en) 2015-06-04
WO2014085318A1 (en) 2014-06-05
KR20150089053A (ko) 2015-08-04
MX2015006809A (es) 2015-08-06
AU2018200323A1 (en) 2018-02-01
BR112015012197A2 (pt) 2017-07-11
CN104812414A (zh) 2015-07-29
BR112015012197A8 (pt) 2019-10-01
EP2925365A1 (en) 2015-10-07
US20150306104A1 (en) 2015-10-29
AU2016262781A1 (en) 2016-12-15
AU2019200881A1 (en) 2019-02-28
JP2019031500A (ja) 2019-02-28
US9408847B2 (en) 2016-08-09
JP2016501221A (ja) 2016-01-18
CA2891938A1 (en) 2014-06-05
RU2015125307A (ru) 2017-01-10

Similar Documents

Publication Publication Date Title
HK1211475A1 (en) Combination therapy
WO2013188783A8 (en) Deuterated derivatives of ruxolitinib
HK1216176A1 (zh) 用於治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
MX378263B (es) Terapia de combinación para el tratamiento del cáncer.
WO2015021358A3 (en) Compounds and methods for inhibiting phosphate transport
IL239639A0 (en) A modified spiropyrido {1,2-a} pyrazine derivative and its medicinal use as an HIV integrase inhibitor
HK1210775A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
WO2013003669A3 (en) Compositions, methods of use, and methods of treatment
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EP3081553A4 (en) Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof
HK1206726A1 (en) Imidazotriazinone compounds
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
HK1223304A1 (zh) 包含二甲双胍和二氢槲皮素的药物组合及其用於治疗癌症的用途
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
WO2014160281A3 (en) Method of enhancing delivery of therapeutic compounds to the eye
HK1217092A1 (zh) 治疗性化合物及其用途
WO2012118308A3 (ko) 피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물.
WO2013117744A3 (en) Methods of treating fibrosis
EP3061455A4 (en) Therapeutic agent for ocular disease or prophylactic agent for ocular disease
EP2987786A4 (en) AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
CA2863409A1 (en) N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof